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Background and aims: Lipoprotein(a) (Lp[a]) is a strong genetic risk factor for cardiovascular disease
(CVD). The American Heart Association has prioritised seven cardiovascular health metrics to reduce the
burden of CVD: body mass index, healthy diet, physical activity, smoking status, blood pressure, diabetes
and cholesterol levels (together also known as ideal cardiovascular health). Our objective was to
determine if individuals with high Lp(a) levels could derive cardiovascular beneﬁts if characterized by
ideal cardiovascular health.
Methods: A total of 14,051 participants of the EPIC-Norfolk study were stratiﬁed according to the car-
diovascular health score (based on the number of health metrics with an ideal, intermediate or poor
status). Of them, 1732 had a CVD event during a mean follow-up of 11.5 years. Cox proportional hazards
models were used to describe the association between the cardiovascular health score and Lp(a) level or
genotype (as estimated by the rs10455872 variant) with the risk of CVD.
Results: We observed little or no differences in serum Lp(a) levels across the seven cardiovascular health
metric categories. Among participants with high serum Lp(a) levels 50 mg/dl), those in the highest (i.e.
healthiest) cardiovascular health score category (10e14) had an adjusted hazard ratio for cardiovascular
disease of 0.33 (95% CI ¼ 0.17e0.63, p ¼ 0.001) compared to participants in the lowest (i.e. unhealthiest)
cardiovascular health score category(0e4). Similar results were obtained when we replaced Lp(a) with
rs10455872.
Conclusions: Although Lp(a) levels are only slightly inﬂuenced by cardiovascular health metrics, an ideal
cardiovascular health could substantially reduce CVD risk associated with high Lp(a) levels or genotype.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Lipoprotein(a) [Lp(a]) consists of a cholesterol rich lipoprotein
particle analogous to low-density lipoprotein (LDL), where’Institut universitaire de car-
n Marguerite D'Youville, 2725
(B.J. Arsenault).
r Ireland Ltd. This is an open accesapolipoprotein B-100 (the most abundant protein on LDL particles)
is linked to apolipoprotein (apo)(a) by a disulphide bond. In-
dividuals with Lp(a) levels in the top 20% of the population distri-
bution (i.e. above approximately 50 mg/dL) have a 2e3 fold higher
increased risk of coronary heart disease and stroke [1,2]. In fact,
recent studies suggest that Lp(a) could be one of the strongest
genetic risk factor for cardiovascular disease (CVD) [3]. The LPA
gene is highly polymorphic and one of the strongest determinants
of Lp(a) levels is a copy number variation (CNV) at the LPA locus
encoding the number of KIV-2 repeats [4]. The single nucleotides article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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associated with KIV-2 repeats and Lp(a) levels [5,6]. These genetic
variations at the LPA locus have been suggested to strongly inﬂu-
ence Lp(a) levels by altering its hepatic secretion rate [4]. Up to 90%
of the variance in circulating Lp(a) could be explained by genetic
factors [7]. Lp(a) is the preferential carrier of oxidized phospho-
lipids in the blood [8], which may be the underlying reason for its
atherogenic potential.
In 2010, a European Atherosclerosis Society Consensus Panel
recommended that Lp(a) levels should be measured in individuals
with premature CVD (or with a family history of premature CVD),
familial hypercholesterolemia, recurrent CVD despite statin treat-
ment or intermediate cardiovascular risk [1]. However, even in
these populations, Lp(a) is currently not routinely measured. The
lack of a consensus on a validated and standardized Lp(a) assay, our
incomplete understanding of the atherogenecity of Lp(a) and
relative unawareness of Lp(a) amongst health care providers
probably are factors that could explain why Lp(a) is not routinely
measured. Moreover, a clinically validated speciﬁc therapy against
Lp(a) is not available.
The American Heart Association (AHA) 2020 Strategic Impact
Goals introduced the concept of ideal cardiovascular health, which
includes seven cardiovascular health metrics, namely body mass
index, a healthy diet, physical activity, smoking status, blood
pressure, fasting plasma glucose and cholesterol levels [9]. Over the
past 5 years, several prospective studies have shown that compared
to people who meet few of the criteria of ideal cardiovascular
health, those with ideal cardiovascular health have a 80e90% lower
risk of CVD events [10e12]. Whether individuals with high Lp(a)
can reduce their risk of cardiovascular events by controlling other
risk factors such as those of the AHA's ideal cardiovascular health is
unknown. In this study, we hypothesised that Lp(a) levels will be
comparable across the seven healthy lifestyle risk factors and that
individuals with high Lp(a) levels (or carriers of G allele of the
Lp(a)-raising SNP rs10555872) are at lower risk of cardiovascular
events if they are characterized by ideal cardiovascular health. We
tested these hypotheses in the European Prospective Investigation
into Cancer and Nutrition (EPIC)-Norfolk study.
2. Materials and methods
2.1. Study design
The EPIC-Norfolk prospective population study is a population-
based cohort of 25,639 men and women, aged between 39 and 79
years, resident in Norfolk, United Kingdom. The design and
methods of the study have been described previously [13]. Partic-
ipants were recruited from age-sex registers of general practices in
Norfolk as part of the 10-country collaborative EPIC study. The
study cohort was closely similar to UK population samples formany
characteristics, including anthropometry, blood pressure and lipids,
but with a lower proportion of smokers. At the baseline survey
conducted between 1993 and 1997, participants completed a
detailed health and lifestyle questionnaire. Blood was taken by
venipuncture into plain and citrate tubes. Blood samples were
processed for various assays at the Department of Clinical
Biochemistry, University of Cambridge, or stored at 80 C.
Participants were identiﬁed as having been hospitalised or
having died because of a cardiovascular event if the corresponding
International Classiﬁcation of Disease (ICD)-10 code was recorded
as the underlying cause of hospitalisation or mortality. Hospitalised
participants were identiﬁed using their unique National Health
Service number linked with the East Norfolk Health Authority
(ENCORE) database. The ENCORE database identiﬁed all hospital
contacts throughout England and Wales for residents of Norfolk.Death certiﬁcates were coded by trained nosologists according to
ICD-10. Deaths or hospitalisations were attributed to coronary
heart disease (CHD) if the underlying cause was coded by as ICD-10
codes 120e125, which encompass the clinical spectrum of CHD,
including unstable angina, stable angina and myocardial infarction.
Deaths or hospitalisations were attributed to stroke if the under-
lying cause was coded as ischaemic (I63, I65, I66) or haemorrhagic
stroke (I60e62). CVD was deﬁned as either a CHD or stroke. The
follow-up was censored on 31 March 2008. The study protocol was
approved by the Norwich District Health Authority Ethics Com-
mittee and all participants gave written informed consent.
2.2. Deﬁnition of cardiovascular health metrics
Ideal cardiovascular health metrics were classiﬁed as ideal, in-
termediate or poor according the seven risk factors identiﬁed by
the AHA, as previously described [12]. Body mass index (BMI) was
classiﬁed as ideal if < 25 kg/m2, as intermediate if 25e30 kg/m2 or
as poor if  30 kg/m2. A healthy diet score (HDS) was based on
intake of ﬁve dietary components. The ﬁrst component was the
intake of sufﬁcient amounts of fruit and vegetables; a consumption
of 4.5 ormore cups per daywas classiﬁed asmeeting the guidelines.
Second, the weight of estimated daily ﬁsh consumption was
multiplied by seven and divided by 3.5 oz (portion size); if the value
was 2, the participant was considered to consume two or more
servings per week. Third, for ﬁbre-rich whole grains, participants
consuming three or more servings per day of 1 oz each were
considered to meet the guidelines. The fourth and ﬁfth HDS com-
ponents were low sodium intake (<1500 mg per day was classiﬁed
as healthy) and low consumption of sugar-sweetened beverages
(<450 kcal per week was classiﬁed as healthy). The HDS was
calculated as the sum of the number of healthy food items, yielding
a HDS range of 0e5. HDS was categorised as ideal (4), interme-
diate (2e3), or poor (<2). Physical activity was deﬁned as ideal,
intermediate and poor if the status was active, moderately active or
moderately inactive, and inactive, respectively, as previously
described [14]. Smoking status was classiﬁed as ideal, intermediate
or poor if the study participant had never smoked, previously
smoked, or was a current smoker, respectively. Blood pressure was
deﬁned as ideal if systolic pressure was <120 mmHg and diastolic
pressure was <80 mmHg, as intermediate if systolic pressure was
120e139 mmHg or diastolic pressure was 80e89 mmHg without
antihypertensive drug treatment or if the blood pressure was at
goal on treatment, or poor if systolic pressure was 140 mmHg or
diastolic pressure was 90 mmHg. Total cholesterol levels were
classiﬁed as ideal (<5.2 mmol/L), intermediate (5.2e6.2 mmol/L) or
when cholesterol levels were treated to goal, or poor (6.2 mmol/
L). Diabetes mellitus status was ascertained by means of (1) self-
report of diabetes medication use or (2) a Hba1c  6.5 mmol/L.
Participants meeting one of these criteria were attributed a value of
0 while individuals without diabetes mellitus were attributed a
value of 2.
The overall cardiovascular health score (CHS) was calculated
based on these seven health metrics, giving 2 points for an ideal
metric, 1 point for an intermediate metric, and 0 points for a poor
metric, thus yielding an overall CHS between 0 and 14. The CHSwas
divided into three categories as follows: 0e4 (unhealthy), 5e9
(intermediate) and 10e14 (healthy).
2.3. Genotyping and laboratory measurements
The rs10455872 genetic variant was genotyped using Custom
TaqMan® SNP Genotyping Assays (Applied Biosystems,Warrington,
UK). The genotyping assayswere carried out using 10 ng of genomic
DNA in a 2.5 ml reaction volume on 384-well plates using a G-Storm
Fig. 1. Cardiovascular disease event rates (bars) and hazard ratios for incident car-
diovascular disease. In patients classiﬁed on the basis of ideal cardiovascular health
categories and Lp(a) levels (A) and rs10455872 carrier status (B) after adjusting for age
and sex. Median (interquartile range) Lp(a) levels are also presented in each categories.
N. Perrot et al. / Atherosclerosis 256 (2017) 47e52 49GS4 Thermal Cycler (GRI, Rayne, UK). The ABI PRISM® 7900HT
Sequence Detection System (Applied Biosystems, Warrington, UK)
was used for end-point detection and allele calling. The SNP passed
the quality control criteria in the EPIC-Norfolk study (call
rate > 95%, blind duplicate concordance  95%). Various laboratory
measurements including a conventional lipid proﬁle, were per-
formed at baseline as previously described [13]. When additional
funding became available in 2010, additional measurements were
performed in a subset of the cohort with available stored frozen
blood samples. Lp(a) levels were measured with an immuno-
turbidimetric assay using polyclonal antibodies directed against
epitopes in apolipoprotein(a) (Denka Seiken, Coventry, United
Kingdom), as previously described [15]. This assay has been shown
to be apolipoprotein(a) isoform-independent.
2.4. Statistical analyses
Baseline characteristics of study participants were compared
between participants with high vs. low Lp(a) levels using an un-
paired Student t-test for continuous variables with a normal dis-
tribution or a chi-square test for categorical variables. Differences in
median Lp(a) levels across cardiovascular health metrics with the
exception of diabetes mellitus were tested using Kruskal Wallis
one-way analysis. For the difference in median Lp(a) levels across
the diabetes mellitus group, a Mann-Whitney U test was per-
formed. The differences in percentages of participants with high
Lp(a) levels (>50 mg/dL) and rs10455872 carriers across categories
of ideal cardiovascular health metrics was tested using chi-square
analysis. Cox proportional hazards models were used to calculate
hazard ratios (HR) and corresponding 95% conﬁdence interval (95%
CI) for the risk of future CHD in participants separated on the basis
of cardiovascular health metrics and Lp(a) levels (or genotype).
Regression models were tested before and after adjustment for
potential confounding risk factors such as age and sex. The inter-
action terms between Lp(a) and cardiovascular health and
rs10455872 and cardiovascular health were calculated with the use
of Cox proportional hazard models. Statistical analyses were per-
formed using SPSS software version 20.
3. Results
A total of 14,051 participants with a complete data set available
for ideal cardiovascular health metrics and Lp(a) levels were
included in this analysis. Of them, 1732 had a CVD event during a
mean follow-up of 11.5 years. The baseline characteristics of the
study participants are presented in Table 1 for the entire study
sample separated on the basis of Lp(a) levels (< or 50 mg/dL).
There were no sex and age differences between participants with
high vs. low Lp(a) levels. Body mass index, blood pressure, the
percentage of participants with diabetes mellitus or smokers was
also comparable between participants with high vs. low Lp(a).
Cholesterol levels were higher in participants with high Lp(a). With
the exception of sodium intake, all other intake parameters were
not different in patients with high vs. low Lp(a) for healthy diet
components or physical activity habits.
Table 2 presents median Lp(a) levels in patients with ideal, in-
termediate or poor cardiovascular health metrics. Lp(a) levels were
signiﬁcantly different across diet and physical activity categories
but these differences were very small and the percentage of par-
ticipants with Lp(a) levels 50 mg/dL or carriers of the G allele of
rs10455872 was not different across physical activity and diet
categories. As anticipated, cholesterol levels were different across
Lp(a) categories, most likely because Lp(a) carries cholesterol.
Consequently, Lp(a) levels appeared to be slightly inﬂuenced by the
presence/absence of the cardiovascular health score.The associations between the cardiovascular health score, Lp(a)
levels and cardiovascular outcomes are presented in Fig. 1. Fig. 1A
shows that among patients with high Lp(a), those with ideal car-
diovascular health have a relative risk of CVD of 0.33 (95% CI,
0.17e0.63, p < 0.001) compared to those with poor cardiovascular
health. Our results also show that patients with ideal cardiovas-
cular health and low Lp(a) levels are those with the lowest CVD
event rate (hazard ratio¼ 0.19, 95% CI, 0.12e0.31, p < 0.001). Similar
results were obtained when we replaced Lp(a) with the Lp(a)-
raising allele (G allele of rs10455872). Fig. 1B shows that among
study participants with at least one Lp(a)-raising allele, those with
ideal cardiovascular health have a relative risk of CVD of 0.24 (95%
CI, 0.13e0.42, p < 0.001) compared to those with poor cardiovas-
cular health. Our results also show that patients with ideal car-
diovascular health who did not have the Lp(a)-raising allele are
those with the lowest CVD event rate (hazard ratio ¼ 0.19, 95% CI,
0.13e0.28, p < 0.001). We also computed the interaction terms
between Lp(a) levels (or genotype) and health categories for CVD
risk prediction and found that none were signiﬁcant (data not
shown), which suggests that there is no evidence that the rela-
tionship between health categories and CVD risk is affected by Lp(a)
levels (or genotype).
Table 1
Baseline clinical characteristics of the total study population and the study population separated on the basis of high vs. low lipoprotein(a) levels.
Total Lp(a) levels mg/dl p value
<50 50
(N ¼ 14,051) (N ¼ 12,511) (N ¼ 1540)
Age, years 59.0 (±9.1) 58.9 (±9.1) 59.6 (±8.8) 0.002
Male, % 47.2 (7167) 47.6 (5955) 43.7 (673) 0.004
Body mass index, kg/m2 26.2 (±3.7) 26.2 (±3.7) 26.1 (±3.7) 0.604
Systolic blood pressure, mmHg 135.2 (±18.1) 135.2 (±18.1) 135.0 (±18.0) 0.694
Diastolic blood pressure, mmHg 82.4 (±11.1) 82.4 (±11.1) 82.3 (±10.9) 0.629
Diabetes, % 3.1 (438) 3.1 (390) 3.1 (48) 0.999
Total cholesterol, mmol/L 6.2 (±1.2) 6.1 (±1.2) 6.6 (±1.1) <0.001
LDL cholesterol, mmol/L 4.0 (±1.0) 3.9 (±1.0) 4.4 (±1.0) <0.001
HDL cholesterol, mmol/L 1.4 (±0.4) 1.4 (±0.4) 1.5 (±0.4) <0.001
Triglycerides, mmol/L 1.8 (±1.1) 1.8 (±1.1) 1.8 (±0.9) 0.082
Healthy diet
Fruit and vegetables 4.5 cups per day 74.2% (10425) 74.1% (9266) 75.3% (1159) 0.311
Fish 2 servings per week 47.9% (6726) 47.8% (5984) 48.2% (742) 0.794
Fiber-rich whole grains 3 servings per day 44.5% (6253) 44.5% (5567) 44.5% (686) 0.971
Sodium <1500 mg per day 3.6% (507) 3.5% (434) 4.7% (73) 0.012
Sugar-sweetened beverages 450 kcal per week 42.6% (5988) 42.7% (5337) 42.3% (651) 0.773
Physical activity
Inactive 29.3% (4123) 29.1% (3646) 31.0% (477) 0.47
Moderately inactive 28.4% (3993) 28.5% (3569) 27.5% (424)
Moderately active 23.1% (3242) 23.2% (2899) 22.3% (343)
Active 19.2% (2693) 19.2% (2397) 19.2% (296)
Smoking behaviour
Current 11.5% (1615) 11.4% (1429) 12.1% (186) 0.73
Former 41.7% (5859) 41.8% (5225) 41.2% (634)
Never 46.8% (6577) 46.8% (5857) 46.8% (720)
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Family-based studies and genetic association studies conducted
in the general population have consistently shown that the inter-
individual variation in Lp(a) levels are most likely explained by
genetic factors. In this study, we found that the seven AHA metrics
of ideal cardiovascular health merely inﬂuence Lp(a) levels, which
further supports the notion that lifestyle may not represent a key a
factor in the management of high Lp(a) levels. However, the results
of our study do suggest that among people with high Lp(a) levels,
the management of lifestyle-related factors may reduce cardio-
vascular risk by up to 75%.
Cross-sectional and intervention studies have been performed
to address the impact of physical activity levels and exercise
training on Lp(a) levels. Mora et al. found no association between
physical activity levels and Lp(a) levels in the Women's Health
Study [16] This is in linewith the outcomes of an intervention study
where nine-months of aerobic training in 30 healthy adults was
shown not to have an impact on Lp(a) levels. In patients with type 2
diabetes, resistance training resulted in a decrease in Lp(a) levels
(from 15.4 ± 18 mg/dL to 13.8 ± 18 mg/dL, p ¼ 0.04) [17], but
another study found no such signiﬁcant effect [18]. In our study, a
healthy dietary pattern was not strongly associated with Lp(a)
levels. Dietary intervention studies have, however, suggested that
the macronutrient composition of the diet may inﬂuence Lp(a)
levels. For instance, in a randomized crossover study, Faghihnia
et al. [19] have shown that a 4-week low-fat, high-carbohydrate
diet increased Lp(a) levels compared to a high-fat, low-carbohy-
drate diet in 63 healthy participants. In the Omni Heart trial, Haring
et al. [20] compared the impact of 3 diets (high-carbohydrate, high-
protein and high in unsaturated fats) on Lp(a) levels. Although
changes in Lp(a) were modest (2,1 to 4,7 mg/dL), all diets signiﬁ-
cantly increased Lp(a) levels, with marked heterogeneity among
black and white participants. Investigators who have measured
Lp(a) levels in nutritional intervention studies aiming at reducing
LDL cholesterol levels (with portfolio diet, almonds, ﬂaxseed, etc.)also found little beneﬁts of these interventions with regards to
Lp(a) levels [21e23]. Drugs targeting LDL cholesterol levels such as
statins also have little or no effect on Lp(a) levels. In fact, whereas
most studies showed that statins do not reduce Lp(a) levels, some
studies show that statins could even increase Lp(a) and oxPL levels
[24e26]. Whether people with high Lp(a) levels would derive more
beneﬁts from statin therapy than people with lower Lp(a) levels is
unknown.
Our study has limitations. For instance, our study population
almost exclusively included Caucasians. Therefore, our results may
not be applicable to other populations. Although we provide results
from a large-scale prospective study with a follow-up of 11.5 years,
the true impact of encouraging people (with or without elevated
Lp(a) levels) to improve cardiovascular health by meeting the AHA
criteria on CVD outcomes can only be formally tested in a ran-
domized clinical trial. However, regardless of Lp(a) levels, there are
currently no randomized clinical trials that have documented the
potential beneﬁts of meeting the AHA's criteria for ideal cardio-
vascular health.
The association between Lp(a) levels and CVD risk is strong and
consistent across sexes and ethnicities. Themeasurement of Lp(a) is
clinically useful as it enhances cardiovascular risk reclassiﬁcation
and discrimination, as recently observed in the Bruneck study and
the Copenhagen City Heart Studies [27,28]. To the best of our
knowledge, our study is the ﬁrst to document the beneﬁts of ideal
cardiovascular health in patients with high Lp(a). Previous analyses
within the EPIC-Norfolk dataset have conﬁrmed that high Lp(a)
levels are signiﬁcantly associated with future risk of peripheral
arterial disease, coronary artery disease and aortic stenosis [5,15], a
ﬁnding that underscores the need for compounds that speciﬁcally
target Lp(a) (reviewed in Ref. [29]) as they could provide substantial
cardiovascular beneﬁts to patients with high Lp(a) if properly
tested in cardiovascular outcomes trials. However, our results
suggest that if Lp(a)-lowering therapies should become available,
these should be added on top of lifestyle management and on top of
other agents that target risk factors for CVD such as LDL cholesterol
Table 2
Median Lp(a) level and the percentage of study participants with high Lp(a) levels or carriers of the rs10455872 allele in each category of cardiovascular health metric.
Cardiovascular health metrics Number Median Lp(a) level [IQR] Lp(a) 50 mg/dL rs10455872 G allele carriers
(N ¼ 14,051) (N ¼ 1540) (N ¼ 2100)
Body mass index
Ideal 5748 11.3 (6.1e27.2) 11.3% (651) 15.1% (867)
Intermediate 6398 11.5 (6.3e26.5) 10.8% (689) 14.9% (955)
Poor 1905 11.3 (5.7e25.1) 10.5% (200) 14.6% (278)
p-Value 0.27 0.49 0.87
Healthy diet score
Ideal 1373 11.2 (6.1e25.1) 10.9% (149) 14.2% (195)
Intermediate 8741 11.7 (6.3e27.3) 11.2% (997) 15.4% (1342)
Poor 3937 11.0 (5.58e25.5) 10.5% (419) 14.3% (563)
p-Value 0.004 0.54 0.22
Physical activity
Ideal 2693 11.2 (6.1e27.1) 11.0% (296) 15.4% (414)
Intermediate 7235 11.2 (6.0e25.8) 10.6% (767) 14.6% (1052)
Poor 4123 11.8 (6.4e27.9) 11.6% (477) 15.3% (632)
p-Value 0.018 0.28 0.43
Smoking behaviour
Ideal 6577 11.5 (6.1e27.5) 10.9% (720) 14.9% (982)
Intermediate 5859 11.3 (6.1e26.0) 10.8% (634) 14.8% (866)
Poor 1615 11.4 (6.3e27.9) 11.5% (186) 15.6% (252)
p-Value 0.64 0.73 0.71
Blood pressure
Ideal 2462 10.7 (6.1e25.9) 11.0% (270) 14.3% (352)
Intermediate 5979 11.3 (5.9e26.9) 10.8% (647) 15.3% (912)
Poor 5610 11.8 (6.3e26.7) 11.1% (623) 14.9% (836)
p-Value 0.029 0.89 0.53
Diabetes Mellitus
Yes 428 11.2 (5.9e26.5) 11.0% (48) 15.5% (68)
No 13,613 11.4 (6.1e26.7) 11.0% (1492) 14.9% (2032)
p-Value 0.43 0.99 0.73
Total cholesterol
Ideal 2630 8.7 (5.1e16.8) 4.5% (118) 12.0% (315)
Intermediate 5284 10.7 (5.9e25.0) 9.3% (492) 15.7% (828)
Poor 6137 13.8 (7.1e33.4) 15.2% (930) 15.6% (957)
p-Value <0.001 <0.001 <0.001
Cardiovascular Health Score
Ideal 2893 9.8 (5.6e20.8) 8.4% (243) 13.5% (393)
Intermediate 10,525 11.8 (6.4e28.1) 11.6% (1226) 15.3% (1612)
Poor 633 11.7 (5.8e24.1) 11.2% (71) 15.2% (96)
p-Value <0.001 <0.001 0.06
N. Perrot et al. / Atherosclerosis 256 (2017) 47e52 51and blood pressure in people who cannot manage these risk factors
with lifestyle alone.
It is commonly accepted that one of the barriers to the routine
measurement of Lp(a) levels in clinics is the absence of Lp(a)-
lowering therapy. Although randomized clinical trials will ulti-
mately be required to formally test this hypothesis, our results
suggest that the management of seven other CVD risk factors could
reduce CVD risk in patients with high Lp(a). We believe that our
results should encourage health professionals to measure Lp(a)
levels at least once in their patients and more routinely in patients
treated with lipid-lowering therapy as well as other lifestyle-
related risk factors to properly assess cardiovascular risk. In
conclusion, our results suggest that controlling cardiovascular risk
factors and prescribing physical activity and a healthy diet should
be pivotal for the management of patients with high Lp(a).
Conﬂict of interest
The authors declared they do not have anything to disclose
regarding conﬂict of interest with respect to this manuscript.
Financial support
EPIC-Norfolk is supported by program grants from the Medical
Research Council UK and Cancer Research UK and with additional
support from the European Union, Stroke Association, British HeartFoundation, and Research into Ageing. RV is supported by a grant
from the European Union [TransCard: FP7-603091-2]. BJA holds a
junior scholar award from the Fonds de recherche du Quebec: Sante
(FRQS).
Author contributions
NP designed the statistical analysis plan, interpreted the data
and wrote the manuscript. RV performed statistical analyses,
interpreted the data and reviewed the manuscript. MS coordinated
the genotyping and reviewed the manuscript. SMB performed
statistical analyses, interpreted the data and reviewed the manu-
script. GKH interpreted the data and reviewed themanuscript. NJW
coordinated the study and reviewed the manuscript. KTK coordi-
nated the study and reviewed the manuscript. BJA designed the
statistical analysis plan, interpreted the data and wrote the
manuscript.
Acknowledgements
We would like to thank participants, general practitioners and
staff of the EPIC-Norfolk study.
References
[1] B.G. Nordestgaard, et al., Lipoprotein(a) as a cardiovascular risk factor: current
status, Eur. Heart J. 31 (23) (Oct 21, 2010) 2844e2853, http://dx.doi.org/
N. Perrot et al. / Atherosclerosis 256 (2017) 47e525210.1016/j.yrtph.2016.11.019.
[2] S. Erqou, et al., Lipoprotein(a) concentration and the risk of coronary heart
disease, stroke, and nonvascular mortality, JAMA 302 (Jul 22, 2009) 412.
[3] M. Nikpay, et al., A comprehensive 1,000 Genomes-based genome-wide as-
sociation meta-analysis of coronary artery disease, Nat. Genet. 47 (Oct, 2015)
1121.
[4] F. Kronenberg, G. Utermann, Lipoprotein(a): resurrected by genetics, J. Intern
Med. 273 (Jan, 2013) 6.
[5] B.J. Arsenault, et al., Lipoprotein(a) levels, genotype, and incident aortic valve
stenosis: a prospective mendelian randomization study and replication in a
case-control cohort, Circ. Cardiovasc Genet. 7 (Jun, 2014) 304.
[6] P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, B.G. Nordestgaard, Geneti-
cally elevated lipoprotein(a) and increased risk of myocardial infarction, JAMA
301 (Jun 10, 2009) 2331.
[7] E. Boerwinkle, et al., Apolipoprotein(a) gene accounts for greater than 90% of
the variation in plasma lipoprotein(a) concentrations, J. Clin. Investig. 90 (Jul,
1992) 52.
[8] C. Bergmark, et al., A novel function of lipoprotein [a] as a preferential carrier
of oxidized phospholipids in human plasma, J. Lipid Res. 49 (Oct, 2008) 2230.
[9] D.M. Lloyd-Jones, et al., Deﬁning and setting national goals for cardiovascular
health promotion and disease reduction: the American Heart Association's
strategic Impact Goal through 2020 and beyond, Circulation 121 (Feb 2, 2010)
586.
[10] A. Akesson, S.C. Larsson, A. Discacciati, A. Wolk, Low-risk diet and lifestyle
habits in the primary prevention of myocardial infarction in men: a
population-based prospective cohort study, J. Am. Coll. Cardiol. 64 (Sep 30,
2014) 1299.
[11] A.R. Folsom, et al., Community prevalence of ideal cardiovascular health, by
the American Heart Association deﬁnition, and relationship with cardiovas-
cular disease incidence, J. Am. Coll. Cardiol. 57 (Apr 19, 2011) 1690.
[12] S. Lachman, et al., Ideal cardiovascular health and risk of cardiovascular events
in the EPIC-Norfolk prospective population study, Eur. J. Prev. Cardiol. 57 (16)
(Sep 2, 2015) 1690e1696.
[13] N. Day, et al., EPIC-Norfolk: study design and characteristics of the cohort.
European Prospective Investigation of Cancer, Br. J. Cancer 80 (Suppl 1) (Jul,
1999) 95.
[14] N.J. Wareham, et al., Validity and repeatability of a simple index derived from
the short physical activity questionnaire used in the European Prospective
Investigation into Cancer and Nutrition (EPIC) study, Public health Nutr. 6
(Jun, 2003) 407.
[15] D. Gurdasani, et al., Lipoprotein(a) and risk of coronary, cerebrovascular, and
peripheral artery disease: the EPIC-Norfolk prospective population study,
Arterioscler. Thromb. Vasc. Biol. 32 (Dec, 2012) 3058.
[16] S. Mora, N. Cook, J.E. Buring, P.M. Ridker, I.M. Lee, Physical activity and
reduced risk of cardiovascular events: potential mediating mechanisms,Circulation 116 (Nov 6, 2007) 2110.
[17] H. Hamasaki, et al., Associations of low-intensity resistance training with body
composition and lipid proﬁle in obese patients with type 2 diabetes, PLoS One
10 (2015) e0132959.
[18] N.P. Kadoglou, et al., The effects of resistance training on ApoB/ApoA-I ratio,
Lp(a) and inﬂammatory markers in patients with type 2 diabetes, Endocrine
42 (Dec, 2012) 561.
[19] N. Faghihnia, S. Tsimikas, E.R. Miller, J.L. Witztum, R.M. Krauss, Changes in
lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat
high-carbohydrate diet, J. Lipid Res. 51 (Nov, 2010) 3324.
[20] B. Haring, M.C. von Ballmoos, L.J. Appel, F.M. Sacks, Healthy dietary in-
terventions and lipoprotein (a) plasma levels: results from the Omni Heart
Trial, PLoS One 9 (2014) e114859.
[21] D.J. Jenkins, et al., Dose response of almonds on coronary heart disease risk
factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), ho-
mocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover
trial, Circulation 106 (Sep 10, 2002) 1327.
[22] D.J. Jenkins, et al., The effect of combining plant sterols, soy protein, viscous
ﬁbers, and almonds in treating hypercholesterolemia, Metabolism 52 (Nov,
2003) 1478.
[23] S. Dodin, et al., Flaxseed on cardiovascular disease markers in healthy
menopausal women: a randomized, double-blind, placebo-controlled trial,
Nutrition 24 (Jan, 2008) 23.
[24] R. Capoulade, et al., Oxidized Phospholipids, Lipoprotein(a), and Progression
of calciﬁc aortic valve stenosis, J. Am. Coll. Cardiol. 66 (Sep 15, 2015) 1236.
[25] A.E. Fraley, et al., Relationship of oxidized phospholipids and biomarkers of
oxidized low-density lipoprotein with cardiovascular risk factors, inﬂamma-
tory biomarkers, and effect of statin therapy in patients with acute coronary
syndromes: results from the MIRACL (Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering) trial, J. Am. Coll. Cardiol. 53 (Jun 9, 2009)
2186.
[26] S.H. Choi, et al., Relationship between biomarkers of oxidized low-density
lipoprotein, statin therapy, quantitative coronary angiography, and
atheroma: volume observations from the REVERSAL (Reversal of Atheroscle-
rosis with Aggressive Lipid Lowering) study, J. Am. Coll. Cardiol. 52 (Jul 1,
2008) 24.
[27] P. Willeit, et al., Discrimination and net reclassiﬁcation of cardiovascular risk
with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study,
J. Am. Coll. Cardiol. 64 (Sep 2, 2014) 851.
[28] P.R. Kamstrup, A. Tybjaerg-Hansen, B.G. Nordestgaard, Extreme lipoprotein(a)
levels and improved cardiovascular risk prediction, J. Am. Coll. Cardiol. 61
(Mar 19, 2013) 1146.
[29] J.C. van Capelleveen, F.M. van der Valk, E.S. Stroes, Current therapies for
lowering lipoprotein(a), J. Lipid Res. 57 (9) (Dec 4, 2015) 1612e1618.
